By comparison, when HPC families that include members with a history of breast or ovarian cancer are screened for BRCA2 mutations, no excess of protein-truncating BRCA2 mutations is found (Agalliu et al, 2007). The gene discussed is BRCA2; the disease is ovarian cancer.